Radiopharm Theranostics (RADX) Common Equity (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Common Equity for 2 consecutive years, with $42.9 million as the latest value for Q2 2025.
- Quarterly Common Equity rose 56.73% to $42.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $42.9 million through Jun 2025, up 56.73% year-over-year, with the annual reading at $42.9 million for FY2025, 56.73% up from the prior year.
- Common Equity for Q2 2025 was $42.9 million at Radiopharm Theranostics, up from $27.4 million in the prior quarter.
- The five-year high for Common Equity was $42.9 million in Q2 2025, with the low at $27.4 million in Q2 2024.